Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisPharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trialsBiologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis.Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) - A prospective, multicenter, single arm pilot clinical trial.Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate respondersEfficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia®as Biological Intensive Treatment for RA (ORBIT) studyEfficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study
P2860
Q24185797-7BDA5D58-80A3-459A-AAF0-8B06A9D05A54Q27015772-C19AAC43-AF85-46B4-BE39-AB022FF45C92Q30235341-56283FDE-0524-408E-9823-561A7BA5A3A0Q34172853-CBCC387C-E4F5-44AB-9FA5-35F8C702CD6EQ35214632-F93A47EA-9B0F-46CF-8D2A-DC80B5FEA7B0Q36195284-DF5A3BEB-DDE6-4D1F-A921-EFFF9D7C57DDQ38212142-155EB668-4248-4B59-BF1B-1792A3B5B06EQ38939820-CC135C1D-85A7-4E60-AC0C-711FEFAC925EQ40374825-0E1D8D18-9168-4853-A31C-607EDCF73824Q53441582-277BD621-EF0C-488F-AED8-9E543C7DECACQ53527795-A90CA335-7C7A-4722-B4A0-957B8D7A1B6DQ58204629-51CBE3C8-3CE5-4C89-95FA-2CBC1C32F5E6Q58204675-B7B85851-DBA3-4EC5-A978-E45365C33235Q58204680-93311675-4387-4CBF-B88E-F1554818AE4D
P2860
Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Phase II dose-response study o ...... uate response to methotrexate.
@en
Phase II dose-response study o ...... uate response to methotrexate.
@nl
type
label
Phase II dose-response study o ...... uate response to methotrexate.
@en
Phase II dose-response study o ...... uate response to methotrexate.
@nl
prefLabel
Phase II dose-response study o ...... uate response to methotrexate.
@en
Phase II dose-response study o ...... uate response to methotrexate.
@nl
P2093
P2860
P1433
P1476
Phase II dose-response study o ...... uate response to methotrexate.
@en
P2093
Ami Yamamoto
Eiichi Suematsu
Japan Abatacept Study Group
Nobuyuki Miyasaka
Shigeru Honjo
Syuji Ohta
Taisuke Nitobe
Tsukasa Matsubara
P2860
P304
P356
10.3109/S10165-012-0668-Z
P577
2012-06-09T00:00:00Z